RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
CONCLUSION: Liposomal irinotecan and topotecan demonstrated similar median OS and PFS in patients with relapsed SCLC. Although the primary end point of OS was not met, liposomal irinotecan demonstrated a higher ORR than topotecan. The safety profile of liposomal irinotecan was consistent with its known safety profile; no new safety concerns emerged.PMID:38648575 | DOI:10.1200/JCO.23.02110 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: David R Spigel Afshin Dowlati Yuanbin Chen Alejandro Navarro James Chih-Hsin Yang Goran Stojanovic Maria Jove Patricia Rich Zoran G Andric Yi-Long Wu Charles M Rudin Huanyu Chen Li Zhang Stanley Yeung Fawzi Benzaghou Luis Paz-Ares Paul A Bunn RESILIENT Tr Source Type: research
PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis
Leptomeningeal metastasis (LM) of small cell lung cancer (SCLC) is a highly detrimental occurrence associated with severe neurological disorders, lacking effective treatment currently. Proteolysis-targeting ch... (Source: BMC Cancer)
Source: BMC Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Min-xing Shi, Xi Ding, Liang Tang, Wei-jun Cao, Bo Su and Jie Zhang Tags: Research Source Type: research
Abnormal expression of LCA and CD43 in SCLC: a rare case report and brief literature review
To present an unusual case of abnormal LCA expression and CD43 in SCLC and to review the reported literature to avoid potential diagnostic pitfalls. (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - April 22, 2024 Category: Respiratory Medicine Authors: Zhe Cai, Linwei Zuo, Fangfang Hu, Huiyan You, Xiangtong Lu, Shousheng Liao, Fanrong Liu, Lixiang Li and Wenyong Huang Tags: Case Report Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Cell Research - April 17, 2024 Category: Cytology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Cell Research)
Source: Cell Research - April 17, 2024 Category: Cytology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Cancer Control)
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Pre-existing IFNg-driven immunity and mitochondrial metabolism seem correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.PMID:38630755 | DOI:10.1158/1078-0432.CCR-24-0104 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Melina Peressini Rosario Garcia-Campelo Bartomeu Massuti Cristina Marti Manuel Cobo Vanesa Guti érrez Manuel D ómine Jose Fuentes Margarita Majem Javier de Castro Juan Felipe Cordoba Maria Pilar Diz Dolores Isla Emilio Esteban Enric Carcereny Laia Vila Source Type: research
Impact of immune ‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
ConclusionsThe results of this study show that immune-related adverse events are associated with improved survival outcomes in patients with extensive-stage small cell lung cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Tadashi Nishimura,
Hajime Fujimoto,
Takumi Fujiwara,
Kentaro Ito,
Atsushi Fujiwara,
Hisamichi Yuda,
Hidetoshi Itani,
Masahiro Naito,
Shuji Kodama,
Kazuki Furuhashi,
Akihiko Yagi,
Haruko Saiki,
Taro Yasuma,
Tomohito Okano,
Atsushi Tomaru,
Mo Tags: RESEARCH ARTICLE Source Type: research
